CUSTOMIZE: Implementation-Effectiveness Study of Long-Acting Cabotegravir and Rilpivirine Injection in US Healthcare Settings

July 18-21, 2021; Virtual
In this real-world study, healthcare staff across a variety of clinic types found the implementation of monthly injectable cabotegravir + rilpivirine both feasible and acceptable despite disruptions due to COVID-19.
Format: Microsoft PowerPoint (.ppt)
File Size: 239 KB
Released: July 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Download CCO slides reviewing clinically relevant new data reported at IAS 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

Downloadable CCO slides from Rajesh T. Gandhi, MD, on evolving options for first-line ART and switching ART in patients with viral suppression

Babafemi Taiwo, MBBS
Program Director
Rajesh T. Gandhi, MD
Released: September 9, 2021

Expert-authored module providing an overview of the development and clinical application of the antiretroviral agents and classes.

Joseph J. Eron, Jr., MD
Program Director
Daniel R. Kuritzkes, MD
Program Director
Philip Grant, MD
Released: September 2, 2021

Clinical Care Options (CCO) expert commentary by Dr. Josep Llibre on data from the SALSA study on switch to 2-drug ART presented at IAS 2021

Josep M. Llibre, MD, PhD Released: August 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue